From: @biontech.de>

Sent: 24 June 2020 15:40

To: GALLINA Sandra (TRADE); (COMP)

Cc: (TRADE); GAUER Celine (SG);

@pfizer.com;


@pfizer.com

Subject: AW: BioNTech/Pfizer Request for Meeting
Attachments: EC Expression of Interest FINAL..pdf

Dear Sandra ,

We are delighted to share with you our proposal for a supply agreement. As you had requested, we are presenting a joint Pfizer-BioNTech proposal, which should considerably streamline and facilitate our discussions for the way forward.

We are approaching you with what we believe is a very attractive offer for the European Union and its Member States:



We look forward to discussing this proposal with you. Should you confirm your interest, we wish to conclude our talks with you in a matter of days, given the global interest for our vaccine. Both BioNTech and Pfizer teams are fully available to work with you around the clock towards a successful outcome.



Anschrift:

BioNTech SE An der Goldgrube 12 55131 Mainz



Der Inhalt dieser E-Mail ist vertraulich und ausschließlich für den bezeichneten Adressaten bestimmt. Wenn Sie nicht der vorgesehene Adressat dieser E-Mail oder dessen Vertreter sein sollten, so beachten Sie bitte, dass jede Form der Kenntnisnahme, Veröffentlichung, Vervielfältigung oder Weitergabe des Inhalts dieser E-Mail unzulässig ist. Wir bitten Sie, sich in diesem Fall mit dem Absender der E-Mail in Verbindung zu setzen.

The information contained in this email is intended for the personal and confidential use of the addressee only. It may also contain privileged information. If you are not the intended recipient then you are hereby notified that you have received this document in error and that any review, distribution or copying of this document is strictly prohibited. If you have received this communication in error, please notify the sender.